CME Symposium Prior to the AUA Scientific Program
Friday, May 28, 2010 • San Francisco, California
5:00 - 7:00pm • Rooms 120-124 Moscone North
Moscone Convention Center
Program Description:
This symposium will include a discussion of what is currently known about the molecular mechanisms of castration resistance, the scientific background supporting the targeting of different aspects of T cell biology, review treatment options, and discuss sequencing options of second line hormonal manipulations, immunotherapy and chemotherapy in the treatment of CRPC through a series of case-based presentations, the use of an audience response system, and a panel discussion.
Target Audience:
This activity is designed to meet the educational needs of urologists and other health care professionals involved in the treatment of patients with prostate cancer.
Learning Objectives:
- Review the basic concepts of immunotherapy and dendritic cell therapy for patients with CRPC
- Review current clinical trials utilizing immunotherapy for CRPC
- Discuss the relative toxicities of treatments for CRPC including those of secondary hormonal manipulations, chemotherapy, and immune therapy
- As part of the case discussions, demonstrate the optimal timing and sequencing of immunotherapy, bisphosphonate therapy, secondary hormonal treatment, and chemotherapy
- Describe the potential limitations/challenges associated with immunotherapeutic options
Faculty Information:
E. David Crawford, MD
Professor of Surgery, Urology and Radiation Oncology
E. David Crawford Endowed Chair in Urologic Oncology
University of Colorado, Denver Health Sciences Center
Denver, Colorado
Daniel P. Petrylak, MD
Associate Professor of Medicine
Director, Genitourinary Oncology Program
Columbia University Medical Center
New York, New York
Neal D. Shore, MD, FACS
Medical Director
Carolina Urologic Research Center
Atlanta Urology Clinics
Myrtle Beach, South Carolina
Continuing Education Credit:
Grant/Downing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Grant/Downing Education designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
Agenda:
| 5:00 - 5:30pm |
Registration and Dinner |
| 5:30 - 5:50pm |
Introduction to Tumor Immunobiology |
| 5:50 - 6:10pm |
Clinical Background: Immunotherapy Trials in Prostate Cancer |
| 6:10 - 6:30pm |
Case-based Current State of the Art Treatment of Metastatic CRPC |
| 6:30 - 6:50pm |
Sequencing Therapeutic Options for Metastatic CRPC |
| 6:50 - 7:00pm |
Questions and Answers |
